Taxane-induced neuropathy not tied to breast cancer outcome

Taxane-induced neuropathy not tied to breast cancer outcome
For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical Oncology.

(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical Oncology.

Bryan P. Schneider, M.D., of the Eastern Cooperative Oncology Group in Indianapolis, and colleagues conducted a study involving 4,554 women with operable who received chemotherapy (up to four cycles of doxorubicin and cyclophosphamide every three weeks) followed by either paclitaxel every three weeks for four cycles (P3), paclitaxel weekly for 12 cycles (P1), docetaxel every three weeks for four cycles (D3), or docetaxel every week for 12 cycles (D1).

The researchers found that grade 2 to 4 neuropathy occurred in 18, 22, 15, and 13 percent of patients who received at least one taxane dose in the P3, P1, D3, and D1 arms of the study, respectively. No significant relationship was observed between the development of neuropathy and disease-free survival, overall survival, or recurrence-free survival, in a model including age, race, obesity, menopausal status, , nodal status, treatment group, neuropathy, and hyperglycemia.

"Taxane-induced does not correlate with improved outcomes in patients with operable breast cancer treated with adjuvant taxane therapy," the authors write. "This finding provides reassurance that biomarkers predictive for neuropathy will likely not enrich for patients who are more likely to benefit from taxane therapy and may also be useful for the identification of patients who are most likely to benefit from adjunctive therapies to mitigate neuropathy."

Several authors disclosed to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Docetaxel given after doxorubicin reduces recurrence

date Jan 08, 2008

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the Na ...

Recommended for you

DNA blood test detects lung cancer mutations

date 13 hours ago

Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers ...

Tumors prefer the easy way out

date 15 hours ago

Tumor cells become lethal when they spread. Blocking this process can be a powerful way to stop cancer. Historically, scientists thought that tumor cells migrated by brute force, actively pushing through whatever ...

Brain tumors may be new targets of Ebola-like virus

date 15 hours ago

Brain tumors are notoriously difficult for most drugs to reach, but Yale researchers have found a promising but unlikely new ally against brain cancers—portions of a deadly virus similar to Ebola.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.